Frankfurt
03.04.25
08:11 Uhr
0,742 Euro
+0,004
+0,54 %
+0,54 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News | ||
| 17.03. | DIAMYD MEDICAL AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 2025 | 1 | Cision News | ||
| 13.03. | Diamyd Medical AB (publ): Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project | 97 | GlobeNewswire (Europe) | Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments... ► Artikel lesen | |
| 10.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 3 | Cision News | ||
| 28.02. | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million | 3 | Cision News | ||
| 20.02. | DIAMYD MEDICAL AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico | 2 | Cision News | ||
| 18.02. | Diamyd Medical AB (publ): Diamyd Medical's CFO to leave in 2025 | 95 | GlobeNewswire (Europe) | Diamyd Medical announced today that Anna Styrud, CFO, has decided to step down from her position. During her 15 years as CFO, she has successfully navigated the financial markets and played a key role... ► Artikel lesen | |
| 12.02. | Diamyd Medical AB: Diamyd Medical announces expanded financial support from Breakthrough T1D | 352 | PR Newswire | STOCKHOLM, Feb. 12, 2025 /PRNewswire/ -- Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes... ► Artikel lesen | |
| 12.02. | DIAMYD MEDICAL AB: DiamydMedical announces expanded financial support from Breakthrough T1D | 4 | Cision News | ||
| 29.01. | Diamyd Medical AB (publ): Quarterly Report 1 24/25 | 68 | GlobeNewswire (Europe) | September 2024 - November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded... ► Artikel lesen | |
| 21.01. | DIAMYD MEDICAL AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 2 | Cision News | ||
| 13.01. | Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd | 377 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum)... ► Artikel lesen | |
| 10.01. | Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting | 1.365 | PR Newswire | STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 09.01. | DIAMYD MEDICAL AB: Renowned immunology investigator, Alice Long, joins Diamyd Medical's Scientific Advisory Board | 2 | Cision News | ||
| 07.01. | Diamyd Medical AB (publ): New publication highlights safety and potential benefits of redosing Diamyd precision medicine for Type 1 Diabetes | 140 | GlobeNewswire (Europe) | Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal International... ► Artikel lesen | |
| 23.12.24 | DIAMYD MEDICAL AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board | 1 | Cision News | ||
| 13.12.24 | Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process | 380 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved... ► Artikel lesen | |
| 05.12.24 | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 03.12.24 | DIAMYD MEDICAL AB: Annual Report 2023/2024 | 2 | Cision News | ||
| 25.11.24 | DIAMYD MEDICAL AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes | 1 | Cision News |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 184,80 | -2,24 % | AbbVie-Aktie mit Kursgewinnen (193,3778 €) | An der US-amerikanischen Börse liegt die AbbVie-Aktie gegenwärtig im Plus. Das Wertpapier notiert zur Stunde bei 209,14 US-Dollar. Im US-amerikanischen Wertpapierhandel hat sich heute die AbbVie-Aktie... ► Artikel lesen | |
| INNOCAN PHARMA | 0,110 | -5,98 % | Innocan Pharma meldet Ergebnisse für das Gesamtjahr 2024: Verdoppelung des Umsatzes auf 29,4 Millionen US$ | Herzliya, Israel und Calgary, Alberta - 31. März 2025 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTC: INNPF) (das
"Unternehmen" oder "Innocan"), ein pharmazeutisches Technologieunternehmen... ► Artikel lesen | |
| ABBOTT LABORATORIES | 116,00 | -4,59 % | Abbott Laboratories: Pullback als Einstiegschance nach Breakout! | Starke Vorstellung! Rückblick Abbott produziert und vertreibt medizinische Geräte, Ernährungsprodukte, Diagnosegeräte und auch Testkits. Nachdem die Aktie Anfang des Jahres steil nach oben gezogen war... ► Artikel lesen | |
| ZOETIS | 148,16 | -1,67 % | AKO Capital LLP Boosts Position in Zoetis Inc. (NYSE:ZTS) | ||
| CRESCO LABS | 0,650 | +5,18 % | Cresco Labs Aktie: Komplexe Lage droht? | Cresco Labs verzeichnete im Geschäftsjahr 2024 eine beeindruckende finanzielle Entwicklung mit einem Jahresumsatz von 724 Millionen Euro. Trotz dieser positiven Kennzahlen schloss das Unternehmen mit... ► Artikel lesen | |
| CSPC PHARMA | 0,644 | -1,56 % | CSPC Pharmaceutical Group-Aktie leicht im Plus (0,5752 €) | Im Plus liegt derzeit die Aktie der CSPC Pharmaceutical Group . Die Aktie notiert aktuell bei 0,58 Euro. Der Anteilsschein der CSPC Pharmaceutical Group verzeichnet zur Stunde einen Preisanstieg von... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 17,360 | 0,00 % | Tonix Pharmaceuticals Holding: Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year | CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial... ► Artikel lesen | |
| AMARIN | 0,378 | -5,50 % | AMARIN CORP PLC - 8-K, Current Report | ||
| NEKTAR THERAPEUTICS | 0,584 | -4,42 % | Nektar Therapeutics files $300M mixed securities shelf | ||
| AXSOME THERAPEUTICS | 97,22 | -3,93 % | Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More | ||
| WUXI BIOLOGICS | 2,881 | -7,53 % | WUXI BIO (02269): (1) CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG; AND (2) DISCLOSEABLE TRANSACTION - COMPLETION OF THE ASSET TRANSACTION ... | ||
| JAGUAR HEALTH | 4,510 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.Jaguar's... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 15,340 | +0,16 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| DAIICHI SANKYO | 22,270 | -0,40 % | Dividendenbekanntmachungen (28.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABERDEEN GROUP PLC ADR US00108N1000 0,3716 USD 0,3442 EUR ACOM CO LTD JP3108600002 7 JPY 0,0429 EUR ADVANEX INC JP3213400009 20... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,912 | +1,33 % | XORTX Therapeutics Inc. - 6-K, Report of foreign issuer |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,54 % bei einem Aktienkurs von 0,742 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.
